Diabetes — all decisions

The Board remands the Veteran's claim for an increased evaluation for diabetes mellitus type II, to include separate compensable ratings for diabetic retinopathy, hypertension, hypertensive retinopathy, atrial fibrillation, and stroke residuals.

The Board dismissed the Veteran's motion for revision based on clear and unmistakable error (CUE) in an April 2022 rating decision, as it was not properly raised with the AOJ first.

The appeal for service connection for diabetes mellitus was dismissed due to the untimely filing of a VA Form 10182 within one year of the July 2021 rating decision.

The appeal was dismissed due to the Veteran's death while it was pending.

The Board denied the motion for revision based on clear and unmistakable error of the January 16, 2018, Rating Decision that denied an increased disability rating in excess of 20 percent for service-connected type II diabetes mellitus.

The Board remands the issue of entitlement to service connection for diabetes mellitus, type II (DM) due to exposure to Camp Lejeune.

The Board denied service connection for an acquired psychiatric disorder and diabetes mellitus (DM) as there was no evidence of a current disability, in-service incurrence or aggravation, and no medical nexus to service.

The Board remands the claims for service connection for diabetes mellitus, type II and hypertension to correct duty to assist errors that occurred prior to the rating decision on appeal.

The Board granted service connection for chronic obstructive pulmonary disease (COPD) and remanded the claims for hypertension and diabetes mellitus.

The Board granted service connection for diabetes mellitus, finding that it developed due to obesity secondary to the Veteran's service-connected orthopedic disabilities.

The Board granted service connection for various conditions, including neck disability manifested by pain and diabetes mellitus type II, secondary to the Veteran's service-connected bilateral knee degenerative arthritis. The other conditions were also granted as they are caused by the now-service-connected diabetes mellitus type II.

The Board granted an effective date of March 2, 2023 for heart disease and September 28, 2023 for chronic renal failure, while denying earlier effective dates for PTSD, migraines, diabetes mellitus type II, hypertension, and bilateral hearing loss. The Board also granted a 70 percent evaluation for PTSD.

The Board granted service connection for tinnitus and denied service connection for hypertension, heart disease, kidney condition, diabetes, left lower extremity neuropathy, left upper extremity neuropathy, right lower extremity neuropathy, right upper extremity neuropathy, depression, and bilateral hearing loss.

The appeal regarding service connection for diabetes was withdrawn by the Veteran's attorney, and therefore, the claim is dismissed.

The Board remands the claims for service connection for diabetes mellitus type II, a brain tumor, erectile dysfunction, and diabetic sensory peripheral neuropathy to further develop evidence of herbicide exposure.

The Board remands the claims for service connection for diabetes mellitus and related conditions due to insufficient evidence of in-service herbicide exposure.

The Veteran was granted a 10 percent initial rating for hypertension and special monthly compensation at the rate authorized by 38 U.S.C. § 1114(m), (n), and (r)(1) effective from August 10, 2022, to November 7, 2024.

The Board dismissed the veteran's appeals for an increased rating and service connection due to erroneous docketing of the same issues.

The Board remands the claims for service connection for a back disorder, gout, hypertension, a left hand disorder, and type II diabetes mellitus due to a pre-decisional duty to assist error.

The Board denied the Veteran's claim for service connection for diabetes mellitus, type II, as there was no evidence of actual exposure to herbicides and the disease did not manifest within one year of separation from service.